Drug intelligence / Profile preview

VaxxiBi

Development stage: Preclinical
Lead developer: Biom Pharmaceutical
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

VaxxiBi is a proprietary vaccine adjuvant platform developed by Biom Pharmaceuticals, utilizing solid-particle nanoemulsion (SPN) technology. This platform is designed to enhance the immunogenicity of vaccine antigens by providing a stable delivery vehicle that facilitates uptake by antigen-presenting cells (APCs). The SPN structure allows for the loading of various types of antigens, including proteins and nucleic acids, and can be tailored to induce specific types of immune responses. Currently in preclinical development, VaxxiBi is being evaluated for its potential to improve the efficacy of vaccines against infectious diseases and potentially in oncology applications.

Brand names: VaxxiBi

Beyond the preview

Go deeper on VaxxiBi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VaxxiBi.

Explore the full profile